Why Healthcare is an Economic Issue
TheMajority.us treats healthcare not as a partisan battleground but as America's most urgent economic challenge. Every dollar spent on preventable illness, every worker sidelined by untreated conditions, and every entrepreneur trapped in a job for insurance — these are economic losses that weaken America's ability to compete globally.
| Indicator | Data Point | What It Means |
|---|---|---|
| Total US healthcare spend | $5.3 trillion (2024) | 17% of GDP — no other country is close |
| Annual growth rate | 5.8% per year | Outpacing GDP growth every year |
| Americans who delayed care | 1 in 6 (2024) | Due to cost — sicker later, more expensive |
| US drug prices vs. comparable nations | 256% of peer countries | Same pills, American prices |
| Air pollution deaths (fossil fuels) | 91,000 per year | Direct link to healthcare costs |
The Healthcare Ladder — Three Steps, One Direction
The three-step ladder is the platform's strategic spine. Each step solves the prerequisite for the next. Step 1 fixes affordability now. Step 2 builds the supply infrastructure that universal coverage requires. Step 3 delivers universal coverage on a system that can actually handle it.
| Step | Policy | Timeline | Purpose |
|---|---|---|---|
| Step 1 — NOW | Medicare Part D for All: drug costs capped immediately | Immediate | Affordability for all 330M Americans |
| Step 2 — NEAR | Supply-side investment: expand residencies, debt forgiveness, immigrant physician fast-lane, NP expansion, AI diagnostics | 3–7 years | Build the doctor supply to absorb universal coverage |
| Step 3 — LONG | Medicare for All — fully funded, includes doctors and hospitals | 10–15 years | Universal coverage on a system built to handle it |
How Medicare Part D for All is Funded
This is not new government spending. It is a cost reallocation. The money is already being spent — it is just flowing to the wrong places. Three funding streams, redirected:
Stream 1 — Medicare Negotiates Drug Prices Directly
CMS estimated that if Medicare's negotiated prices had been in effect during 2024, they would have saved an estimated $12 billion in net covered prescription drug costs on just the first round of negotiated drugs. The Congressional Budget Office projected $100 billion in savings over 10 years from drug negotiation alone. As negotiation expands — up to 20 additional drugs selected per year starting in 2027 — those savings compound annually.
Stream 2 — Eliminate PBM Middlemen
Three pharmacy benefit managers — CVS Caremark, Express Scripts, and Optum Rx — control nearly 80% of all prescriptions filled in the US, operating a market of almost $600 billion in 2024. Reforming payments to PBMs and other pharmacy middlemen could lower annual US drug spending by nearly $100 billion, according to analysis from the USC Schaeffer Center for Health Policy & Economics.
The math: research shows the current PBM system directly inflates prices — every $1 increase in rebates raises a drug's list price by an average of $1.17. Eliminating this distortion is bipartisan. The Trump administration's April 2025 Executive Order directed review of middlemen “to promote a more competitive, efficient, transparent, and resilient pharmaceutical value chain.”
Stream 3 — Employer Savings Redirected to Medicare
Average annual premiums for employer-sponsored health insurance in 2025 are $9,325 for single coverage and $26,993 for family coverage. In 2024, nearly a quarter of all employer health care spend — 24% — went to pharmacy expenses alone, with employers forecasting an 11–12% increase in pharmacy costs heading into 2026.
When Medicare covers drug costs universally using negotiated prices, employers' largest and fastest-growing cost center shrinks. Those savings are partially redirected as a Medicare contribution — framed not as a tax but as a cost swap: employers pay less in insurance premiums than they save. The net new government expenditure, offset by employer contribution redirects and PBM reform savings, is designed to grow no faster than CPI.
Step 2 — Solving the Doctor Shortage First
The US faces a projected shortage of up to 86,000 physicians by 2036. The bottleneck is not medical school enrollment — it is residency slots. The US now graduates enough new doctors to fill all its residency slots, and then some, but without additional GME positions, many of those graduates cannot complete training. In 2025, over 20% of applicants failed to match — meaning they finished medical school but couldn't become practicing physicians.
The Root Cause
The Balanced Budget Act of 1997 froze the number of Medicare-funded residency positions. Except for 1,200 slots created in 2021 and 2023, that cap has not been significantly raised in nearly 30 years. Congress capped doctor training to cut costs — and America has been paying for it in shortages, longer wait times, and rural healthcare deserts ever since.
The Five-Part Solution
| Solution | How It Works | Timeline |
|---|---|---|
| Lift the 1997 GME cap | The Resident Physician Shortage Reduction Act of 2025 adds 14,000 Medicare-supported residency slots over 7 years. Bipartisan bill — AMA, AHA, and AAMC endorsed. | 2026–2032 |
| Medical school debt forgiveness | 5 years practicing in underserved areas = 100% forgiven. Solves supply AND distribution. | 5–10 years |
| Immigrant physician fast-lane | 9,500+ trained doctors failed to match in 2025. Streamlined credentialing for foreign-trained physicians adds supply immediately. 57% of voters support. | 1–3 years |
| Nurse practitioner scope expansion | 34 states passed 120+ scope of practice bills in 2024. Bridge coverage while physician supply grows. | Immediate |
| AI-assisted diagnostics | One physician effectively serves 3× more patients with AI support tools. See Section 5. | 2–5 years |
AI — The Reason the Time is Right for Medicare for All
Every previous attempt at universal coverage ran into the same wall: the system is not efficient enough to absorb the demand surge, and the drugs are too expensive to cover everyone. Artificial intelligence is dismantling both obstacles simultaneously — and doing it faster than anyone predicted.
AI Collapses Drug Discovery Costs
The traditional path to a new drug costs an average of $2.6 billion and takes 10–15 years, with a staggering 90% of candidates failing in pre-clinical and clinical phases. AI is breaking that math entirely.
In February 2026, Insilico Medicine announced that the first fully AI-designed drug for idiopathic pulmonary fibrosis had completed Phase IIa clinical trials with statistically significant efficacy. The drug was conceived, designed, and optimized using AI in 18 months at a total cost of approximately $6 million — compared to the traditional path of $100–200 million and 6–8 years to the same milestone.
| Metric | Traditional | With AI |
|---|---|---|
| Time to drug candidate | 6–8 years | 18 months |
| Cost to Phase II milestone | $100–200 million | ~$6 million |
| Phase I success rate | 7.9% | 80–90% (AI candidates) |
| Discovery timeline compression | Baseline | 40%+ reduction |
| R&D cost reduction potential | Baseline | Up to 45% |
When it costs $6 million instead of $200 million to discover a drug candidate, the argument that pharma needs 2.5× American pricing to fund R&D collapses. Lower discovery costs mean lower justified drug prices — which directly funds the affordability of Medicare for All.
AI Multiplies Physician Capacity
Physicians in the United States spend between 34 and 55 percent of their workday compiling clinical documentation and reviewing electronic medical records — not treating patients. That is the doctor shortage hiding in plain sight.
Among physicians surveyed by the AMA, 57% said addressing administrative burdens through automation remains the biggest area of opportunity for AI. AI-powered ambient scribing, automated prior authorization, and clinical decision support tools are already converting that administrative time back into patient care — effectively multiplying physician capacity without training a single new doctor.
- AI ambient scribing eliminates up to 55% of documentation time per physician
- AI clinical decision support reduces unnecessary tests and procedures by up to 30%
- AI prior authorization automation resolves 40% of cases without human review
- Telemedicine + AI extends one physician's reach to 3× more patients
AI Reduces Hospitalization Costs
Hospitalizations are the most expensive line item in the US healthcare system. AI shifts the model from reactive to predictive — catching deterioration before it becomes an emergency room visit, flagging high-risk patients before they crash, and keeping people out of hospitals that cost $5,000 a day.
| AI Application | Documented Result | Source |
|---|---|---|
| Predictive analytics for readmission | Up to 50% reduction in hospital readmissions | Healthcare providers, 2025 |
| AI-guided remote patient monitoring | 70% reduction in 30-day readmissions, 38% cost reduction | Documented health system deployments |
| AI-assisted surgery | 20%+ shorter hospital stays, $40B annual savings potential | Healthcare AI statistics, 2026 |
| Massachusetts General Hospital AI | 18% readmission reduction, $3M saved annually | Peer-reviewed study |
| Billing and revenue cycle automation | $18.4B+ annual savings potential across US | William Blair analysis, 2026 |
The economic logic: preventing one readmission saves more than treating ten outpatients. Early detection through AI — catching cancer earlier, flagging cardiac risk before a heart attack, monitoring diabetics before they crash — is the highest-ROI intervention in the entire system.
The Timing Argument — Why Now
Every prior attempt at universal coverage ran into the same wall: the system is not efficient enough to absorb demand, and costs are too high to cover everyone. AI is changing that calculation on four dimensions simultaneously, within the 15-year window of this plan.
| Objection to Universal Coverage | AI Solution | Timeline |
|---|---|---|
| Drug prices too high to cover everyone | AI collapses R&D costs → lower justified prices | Now — first AI drugs in trials |
| Not enough doctors to serve everyone | AI multiplies physician capacity + Step 2 expands residencies | 3–7 years |
| Hospitals too expensive | AI predictive care reduces readmissions 50–70% | Now — deployed in top systems |
| Administrative cost too high | AI automates billing, coding, prior auth → $18.4B+ savings | Now |
Step 3 — Medicare for All, Built on a System That Can Handle It
Medicare for All is not the first step of this plan. It is the destination that Step 1 and Step 2 make possible. By the time Step 3 is fully implemented:
- Drug prices are negotiated and PBM middlemen are reformed (Step 1)
- 14,000 new residency slots have produced 14,000+ additional physicians (Step 2)
- Nurse practitioner scope has expanded to cover primary care gaps (Step 2)
- AI has multiplied physician capacity by 2–3× (Sections 4 and 5)
- Hospital readmissions are 50–70% lower through AI predictive care (Section 5)
- Administrative costs are $18B+ lower through AI automation (Section 5)
The result: a healthcare system that is structurally cheaper, has dramatically more capacity, and can absorb universal enrollment without the cost spike that critics of universal coverage have historically and correctly pointed to.
Mae's Talking Points
These are the canonical short answers that power the Mae persona on Maj AI. Each is crafted to reframe an objection into a majority-supported economic argument.